Total cholesterol and LDL cholesterol were reduced in all trials but there was evidence of heterogeneity of effects .
There was no evidence of any serious harm caused by statin prescription .
Evidence available to date showed that primary prevention with statins is likely to be cost-effective and may improve patient quality of life .
Recent findings from the Cholesterol Treatment Trialists study using individual patient data meta- analysis indicate that these benefits are similar in people at lower ( < 1 % per year ) risk of a major cardiovascular event .
AUTHORS ' CONCLUSIONS Reductions in all-cause mortality , major vascular events and revascularisations were found with no excess of adverse events among people without evidence of CVD treated with statins
BACKGROUND Reducing high blood cholesterol , a risk factor for cardiovascular disease ( CVD ) events in people with and without a past history of CVD is an important goal of pharmacotherapy .
Statins are the first-choice agents .
Previous review s of the effects of statins have highlighted their benefits in people with CVD .
The case for primary prevention was uncertain when the last version of this review was published ( 2011 ) and in light of new data an up date of this review is required .
OBJECTIVES To assess the effects , both harms and benefits , of statins in people with no history of CVD .
The effect of statin therapy on endothelial function in type 2 diabetes without manifest cardiovascular disease.
OBJECTIVE Cardiovascular disease ( CVD ) is the most important cause of mortality in patients with type 2 diabetes and is preceded by endothelial dysfunction . Flow-mediated dilation ( FMD ) is a noninvasive technique for measuring endothelial dysfunction . We aim ed to determine the effect of long-term statin therapy versus placebo on FMD in patients with type 2 diabetes without manifest CVD . RESEARCH DESIGN AND METHODS A r and omized , placebo-controlled , double-blind trial was performed with 250 type 2 diabetic patients . Patients were given 0.4 mg cerivastatin or placebo daily . In August 2001 , when cerivastatin was withdrawn from the market , the 0.4 mg cerivastatin was replaced by 20 mg simvastatin , without deblinding the study . The primary end point was the change in FMD , measured by B-mode ultrasound , after 2 years . RESULTS Determinants of baseline FMD were diabetes duration , common carotid intima-media thickness , and brachial artery diameter . FMD at baseline was 1.51 % in the placebo group and 1.66 % in the statin group and did not change significantly after 2 years . CONCLUSIONS The 2-year statin therapy had no effect on FMD in type 2 diabetes . Statin-induced improvement of cardiovascular risk in patients with type 2 diabetes may be mediated through mechanisms other than increased nitric oxide availability
Total cholesterol and LDL cholesterol were reduced in all trials but there was evidence of heterogeneity of effects .
There was no evidence of any serious harm caused by statin prescription .
Evidence available to date showed that primary prevention with statins is likely to be cost-effective and may improve patient quality of life .
Recent findings from the Cholesterol Treatment Trialists study using individual patient data meta- analysis indicate that these benefits are similar in people at lower ( < 1 % per year ) risk of a major cardiovascular event .
AUTHORS ' CONCLUSIONS Reductions in all-cause mortality , major vascular events and revascularisations were found with no excess of adverse events among people without evidence of CVD treated with statins
BACKGROUND Reducing high blood cholesterol , a risk factor for cardiovascular disease ( CVD ) events in people with and without a past history of CVD is an important goal of pharmacotherapy .
Statins are the first-choice agents .
Previous review s of the effects of statins have highlighted their benefits in people with CVD .
The case for primary prevention was uncertain when the last version of this review was published ( 2011 ) and in light of new data an up date of this review is required .
OBJECTIVES To assess the effects , both harms and benefits , of statins in people with no history of CVD .